Friday, March 5, 2021

No date for Brazil’s national inoculations to begin but Sao Paulo state forges ahead alone

The state government has bought the Chinese vaccine independently, angering President Jair Bolsonaro.

Other News

Pengerusi BN terus gesa sidang Parlimen ketika darurat

BN menganggap kenyataan Menteri Di Jabatan Perdana Menteri Takiyuddin Hassan semalam mencabar kuasa Agong.

PN masih utuh, kata Bersatu

Bersatu menyatakan penghargaan kepada semua parti komponen Perikatan Nasional yang masih setia dengan gabungan itu.

Bersatu says PN still in charge, views Umno decision seriously

The party says its focus is on the economy and the pandemic, and that it takes a serious view of Umno's decision.

Hanya MySejahtera digunapakai bagi solat Jumaat di Selangor berkuat kuasa esok

Sebarang aplikasi pengimbas selain MySejahtera tidak diterima oleh Jais bagi jemaah yang ingin masuk ke dalam masjid dan surau.

BN chief Zahid repeats call for Dewan Rakyat sitting during emergency

The BN chairman also hits out at PAS' Takiyuddin Hassan for ruling out any parliamentary sitting during the virus emergency.

Brazil’s Sao Paulo state has delayed the release of efficacy data for the Covid-19 vaccine developed by China’s Sinovac but kept the planned roll out date for Jan 25, reports Reuters.

Governor Joao Doria said in a radio interview the data would be released on Dec 23, eight days later than planned, to allow for a larger sample size and more complete analysis.

Joao Gabbardo, head of Sao Paulo’s Covid-19 response, said the delay would allow the efficacy analysis to include data from a sample including 151 infected people, making it a definitive rather than a preliminary report.

Sao Paulo has sourced the Chinese vaccine independently of the federal government, angering President Jair Bolsonaro, who has yet to set a date for a national immunisation campaign.

On Sunday, Supreme Court justice Ricardo Lewandowski ordered the federal health ministry to clarify within 48 hours when the federal government plans to begin public vaccinations.

Although Brazil has an enviable record for national vaccinations and a public health system well set up for such campaigns, Bolsonaro has repeatedly denied the seriousness of Covid-19 and is a vaccine sceptic who has said he will not accept a Covid-19 shot himself.

Doria’s public pressure has also irritated health regulator Anvisa, which is increasingly run by Bolsonaro allies.

Last week Sao Paulo’s biomedical centre, the Butantan Institute, began producing the Sinovac vaccine in a process that will have a capacity of one million doses a day.

Despite not having federal approval for the vaccine at a time when the world is scrambling for shots, Sao Paulo’s progress is drawing interest from governors of states across Brazil and countries across Latin America.

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

New cases back over 2,000 but recoveries still ahead

2,063 new cases, 2,922 recoveries.

UK, others agree to fast-track adapted Covid-19 vaccines

The agreement will avert the need for lengthy clinical studies if authorised vaccines are adapted in future, as long as the manufacturers offer 'robust evidence' of their potency and safety.

Australia extends international flight ban for 3 more months

Anyone hoping to enter Australia will have longer to wait as arrivals are limited to the capacity of mandatory quarantine hotels.

Brazil reports second straight day of record Covid-19 deaths

Far-right President Jair Bolsonaro faces sharp criticism for downplaying the new coronavirus, flouting expert advice on containing it with lockdowns and face masks, and over his government's slow pace in vaccinating the population.

AstraZeneca vaccine effective in over-80s, study shows

Stephen Evans, professor of Pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, says the results 'provide further evidence that the vaccines are effective both in an older age group less studied in the trials'.